IL164975A0 - Novel combination - Google Patents

Novel combination

Info

Publication number
IL164975A0
IL164975A0 IL16497504A IL16497504A IL164975A0 IL 164975 A0 IL164975 A0 IL 164975A0 IL 16497504 A IL16497504 A IL 16497504A IL 16497504 A IL16497504 A IL 16497504A IL 164975 A0 IL164975 A0 IL 164975A0
Authority
IL
Israel
Prior art keywords
novel combination
novel
combination
Prior art date
Application number
IL16497504A
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211919A external-priority patent/GB0211919D0/en
Priority claimed from GB0229784A external-priority patent/GB0229784D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of IL164975A0 publication Critical patent/IL164975A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16497504A 2002-05-23 2004-11-01 Novel combination IL164975A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0211919A GB0211919D0 (en) 2002-05-23 2002-05-23 Novel combination
GB0229784A GB0229784D0 (en) 2002-12-20 2002-12-20 Novel combination
PCT/IB2003/001889 WO2003099194A2 (en) 2002-05-23 2003-05-09 Pharmaceutical combination of pde5 inhibitors with ace inhibitors

Publications (1)

Publication Number Publication Date
IL164975A0 true IL164975A0 (en) 2005-12-18

Family

ID=29585817

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16497504A IL164975A0 (en) 2002-05-23 2004-11-01 Novel combination

Country Status (18)

Country Link
EP (1) EP1506015A2 (en)
JP (1) JP2005529927A (en)
KR (1) KR20050004195A (en)
CN (1) CN1655820A (en)
AR (1) AR040090A1 (en)
AU (1) AU2003223071A1 (en)
BR (1) BR0311191A (en)
CA (1) CA2485984A1 (en)
IL (1) IL164975A0 (en)
MX (1) MXPA04010951A (en)
NO (1) NO20045517L (en)
PA (1) PA8574201A1 (en)
PE (1) PE20040514A1 (en)
PL (1) PL374198A1 (en)
RU (1) RU2004133973A (en)
TW (1) TW200407153A (en)
UY (1) UY27816A1 (en)
WO (1) WO2003099194A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
GB0318094D0 (en) * 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
DE102004011512B4 (en) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical preparation containing pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
FR2902009B1 (en) * 2006-06-13 2012-12-07 Bioprojet Soc Civ USE OF A VASOPEPTIDASE INHIBITOR FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
JP2010501577A (en) * 2006-08-24 2010-01-21 サーフェイス ロジックス，インコーポレイティド Compounds with improved pharmacokinetics
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
ES2924478T3 (en) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulation of pharmaceutical tablets for the veterinary medical sector, method of production and use thereof
EP3865120A1 (en) 2013-07-19 2021-08-18 Boehringer Ingelheim Vetmedica GmbH Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
CN110721164B (en) 2013-12-04 2024-09-17 勃林格殷格翰动物保健有限公司 Improved pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
CU23063A3 (en) * 1997-11-12 2005-07-19 Bayer Ag IMIDAZOTRIAZINONES 2-PHENYL REPLACED AS PHOSPHODESTERASE INHIBITORS
DZ3218A1 (en) * 1999-10-11 2001-04-19 Pfizer PYRIMIDINE-7-ONES 5- (2-SUBSTITUTEES-5-HETEROCYCLYLSULPHONYLPYRIDE-3-YL) -DIHYDROPYRAZOLO [4,3-D] AS PHOSPHODIESTERASE INHIBITORS
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
PE20040514A1 (en) 2004-08-24
UY27816A1 (en) 2003-12-31
WO2003099194A2 (en) 2003-12-04
RU2004133973A (en) 2005-09-10
CA2485984A1 (en) 2003-12-04
AU2003223071A1 (en) 2003-12-12
PA8574201A1 (en) 2003-12-19
TW200407153A (en) 2004-05-16
EP1506015A2 (en) 2005-02-16
BR0311191A (en) 2005-03-01
KR20050004195A (en) 2005-01-12
WO2003099194A3 (en) 2004-06-03
NO20045517L (en) 2004-12-17
JP2005529927A (en) 2005-10-06
MXPA04010951A (en) 2005-06-08
PL374198A1 (en) 2005-10-03
CN1655820A (en) 2005-08-17
AR040090A1 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
DE50311874D1 (en) Spirocyclische cyclohexan-derivate
IL166084A0 (en) Novel benzodioxoles
PL371678A1 (en) Novel pyridin- and pyrimidin-derivatives
PL373598A1 (en) Novel benzonaphthyridines
AU2003249738A8 (en) Ostoscope
DE50309217D1 (en) Benzimidazolderivate
AU2003252028A8 (en) Heterodiamondoids
IL163529A0 (en) Novel spinosyn-producing polyketidesynthases
AU2003279495A8 (en) Alert-modeling
DE50303619D1 (en) Reibschweissvorrichtung
DE50308027D1 (en) Cyclohexyl-harnstoff-derivate
DE50307787D1 (en) Isophthalsäurederivate
DE50312412D1 (en) 4-hydroxymethyl-1-aryl-cyclohexylamin-derivative
DE50311133D1 (en) Carbonsäureamide
IL164975A0 (en) Novel combination
DE50310169D1 (en) Lingual-retainer
GB0214784D0 (en) Novel combination
AU2002367810A8 (en) Bis-transition-metal-chelate-probes
DE50304964D1 (en) Handhobelmaschine
GB0225873D0 (en) Combination
AU2003262681A8 (en) Hemo-aide
DE10392833D2 (en) Geotextilie
AU2003253735A8 (en) Vacuolins
AU2002341221A8 (en) Honey-brandy
DE50309021D1 (en) Etherlacton